FDA approved Heparin Sodium in 0.45% Sodium Chloride Injection for Thromboembolic IndicationsFDA approved Premixed Blood Thinner Heparin for Intravenous Use in Hospitals

Not reported in label.

Heparin Sodium in 0.45% Sodium Chloride Injection is indicated for prophylaxis and treatment of venous thrombosis and pulmonary embolism; prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation; treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation); prevention of clotting in arterial and cardiac surgery; prophylaxis and treatment of peripheral arterial embolism; and anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures. Pediatric dosing recommendations are based on clinical experience; there are no adequate and well-controlled studies in pediatric patients.

Administer by intravenous infusion only. Do not use as a catheter lock flush. Do not admix with other drugs. Discard unused portion. Do not use plastic containers in series connection. Do not infuse under pressure. Inspect visually for particulate matter and discoloration; use only if solution is clear and container and seals are intact.

Adult full-dose therapeutic regimens (based on 150 lb/68 kg patient): intermittent IV injection with initial dose 10,000 Units, subsequent doses 5,000 to 10,000 Units every 4 to 6 hours; continuous IV infusion with initial dose 5,000 Units by IV injection, then 20,000 to 40,000 Units every 24 hours. Adjust dosage per coagulation test results. For continuous infusion, determine coagulation time approximately every 4 hours early in treatment; for intermittent injection, perform coagulation tests before each injection early in treatment and at appropriate intervals thereafter. Dosage is considered adequate when APTT is 1.5 to 2 times normal or whole blood clotting time is elevated approximately 2.5 to 3 times control. Periodic platelet counts, hematocrits, and stool occult blood tests are recommended during the entire course of therapy.

Cardiovascular surgery: initial dose not less than 150 units/kg for total body perfusion; frequently 300 units/kg for procedures estimated under 60 minutes or 400 units/kg for longer procedures. Extracorporeal dialysis: follow equipment manufacturer operating directions carefully.

Pediatric guideline: initial 75 to 100 units/kg IV bolus over 10 minutes; maintenance for infants 25 to 30 units/kg/hour (infants under 2 months have highest requirements, average 28 units/kg/hour); children over 1 year 18 to 20 units/kg/hour; older children may require less. Adjust to maintain APTT of 60 to 85 seconds, assuming this reflects anti-Factor Xa level of 0.35 to 0.70.

Converting to warfarin: continue full heparin therapy for several days until INR reaches a stable therapeutic range, then discontinue without tapering. Converting to oral anticoagulants other than warfarin: stop IV infusion immediately after first oral anticoagulant dose, or for intermittent IV administration start oral anticoagulant 0 to 2 hours before the next heparin dose.

Trial data not available in label.

Not reported in label.

Not reported in label.